Articles from OBI Pharma USA, Inc.

OBI Pharma Signs Collaboration and License Agreement with Novartis
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies.
By OBI Pharma USA, Inc. · Via ACCESS Newswire · November 16, 2026
Articles from OBI Pharma USA, Inc. | Hannibal Courier - Post